RxDoctor Payments Data

Umair Minhas, MD

Gastroenterology · Anderson, INNPI 1083001655

Payments from drug & device makers

$9,324in general payments, 2019–2025

Across 367 payments — averaging $25.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • AbbVie$2K
  • Sanofi$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$667
  • Regeneron Healthcare Solutions, Inc.$513
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$415
  • plus $3K from 28 others

What the payments were for

  • Consulting fees$1,20013%
  • Food & beverage$8,01786%
  • Education$1071%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,324 in reported general payments places this provider in the 75th percentile of 323 gastroenterology providers in Indiana.

See all gastroenterology providers in Indiana

Medicare billing

Part B allowed, 2024
$75,007
Medicare patients
255
Services billed
664

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide47$58,174
ZenpepLipase/Protease/Amylase11$54,764
XifaxanRifaximin17$51,155
Mesalamine19$4,874
Budesonide EcBudesonide13$4,719
Lubiprostone27$3,712
Pantoprazole Sodium135$1,810
Ursodiol12$1,604
Omeprazole74$1,005
Esomeprazole Magnesium33$898
Ondansetron OdtOndansetron20$845
Nortriptyline Hcl39$588
Dicyclomine Hcl27$527
Prochlorperazine Maleate20$421
Lactulose16$408

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,550$58,17447 claims
Aimmune Therapeutics, Inc.Zenpep$119$54,76411 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$415$51,15517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 323 gastroenterology providers in Indiana.

Other gastroenterology in Anderson

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →